Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16746-16756

  Kim, Jin Soo ^a,c   Kim, Edward S ^a   Liu, Diane ^a   Jack Lee, J ^a   Behrens, Carmen ^a   Lippman, Scott M ^a   Hong, Waun Ki ^a   Wistuba, Ignacio I ^a   Lee, Euni ^b   Lee, Ho Young ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Seoul National University   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

Author keywords

Insulin like growth factor 1 receptor; Non small cell lung cancer; Prognosis; Tissue microarray

Indexed keywords

MESSENGER RNA; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; ENZYME ACTIVATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, IGF TYPE 1; TISSUE ARRAY ANALYSIS;

EID: 84937886305     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3796     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63:11-30.
3. Keith RL and Miller YE. Lung cancer chemoprevention: current status and future prospects. Nature reviews Clinical oncology. 2013; 10:334-343.
4. Johnson DH, Schiller JH and Bunn PA, Jr. Recent clinical advances in lung cancer management. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32:973-982.
5. Tao Y, Pinzi V, Bourhis J and Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. Nature clinical practice Oncology. 2007; 4:591-602.
6. Dziadziuszko R, Camidge DR and Hirsch FR. The insulinlike growth factor pathway in lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2008; 3:815-818.
7. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya- Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M and Pao W. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti- IGF-1R antibody (R1507). Plos One. 2009; 4:e7273.
8. Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T and Mishima M. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer. Clinical lung cancer. 2012; 13:385-390.
9. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Jr., Johnson FM, Green S and Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:2516-2522.
10. Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ and Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32:2059-2066.
11. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA and Santoro A. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2010; 21:562-567.
12. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Jr., Varella-Garcia M and Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:2174-2180.
13. Kikuchi R, Sonobe M, Kobayashi M, Ishikawa M, Kitamura J, Nakayama E, Menju T, Miyahara R, Huang CL and Date H. Expression of IGF1R is associated with tumor differentiation and survival in patients with lung adenocarcinoma. Annals of surgical oncology. 2012; 19 Suppl 3:S412-420.
14. Fidler MJ, Shersher DD, Borgia JA and Bonomi P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Therapeutic advances in medical oncology. 2012; 4:51-60.
15. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511:543-550.
16. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489:519-525.
17. Kim LC, Song L and Haura EB. Src kinases as therapeutic targets for cancer. Nature reviews Clinical oncology. 2009; 6:587-595.
18. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Mameli MG, Daddi G, Cavaliere A, Tonato M and Crino L. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2009; 20:842-849.
19. Reinmuth N, Kloos S, Warth A, Risch A, Muley T, Hoffmann H, Thomas M and Meister M. Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. Human pathology. 2014; 45:1162-1168.
20. Nair PN, De Armond DT, Adamo ML, Strodel WE and Freeman JW. Aberrant expression and activation of insulinlike growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene. 2001; 20:8203-8214.
21. Arbet-Engels C, Tartare-Deckert S and Eckhart W. C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor. The Journal of biological chemistry. 1999; 274:5422-5428.
22. Gualberto A, Dolled-Filhart MP, Hixon ML, Christensen J, Rimm DL, Lee AV, Wang Y, Pollak M, Paz-Ares LG and Karp DD. Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. Journal of Clinical Oncology. 2009; 27.
23. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, et al. Sex determining region Y-Box 2 (SOX2) is a potential celllineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. Plos One. 2010; 5:e9112.
24. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, Hong WK and Lee HY. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene. 2004; 23:6569-6580.
25. Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y. The new World Health Organization classification of lung tumours. The European respiratory journal. 2001; 18:1059-1068.
26. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba, II and Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012; 118:2454-2465.
27. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6:pl1.
28. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2:401-404.
29. Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA, Jr., Santoro A, Franklin WA, Varella-Garcia M, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2006; 17:1120-1127.